HCW Biologics Inc. (HCWB) Institutional Ownership

Ownership Summary

The institutional landscape for HCW Biologics Inc. (NASDAQ:HCWB) includes 14 filers as of the latest reporting cycle ending December 2025.

• HCW Biologics saw its institutional ownership percentage rose to 19.4% in December 2025 from 5.5% in September 2025.
• The company experienced a 253.87% quarterly change in institutional shares held, alongside a decrease of 26.32% in total owners annually.
• The latest 13F cycle for HCW Biologics reveals that of 14 total investors, 8 funds grew their exposure, whereas 3 reduced theirs and 3 made no changes.
• The total number of shares held by institutions in HCW Biologics increased to 436.93K as of December 2025, a net change of up by 313.46K shares quarter on quarter, and down 2.69Mn shares year over year.
• The top institutional stake in HCW Biologics as of December 31, 2025 belongs to ARMISTICE CAPITAL, LLC, which owns 300.18K shares, or 13.31% of the company.
• Among the most significant buyers of HCW Biologics during December 2025 were ARMISTICE CAPITAL, LLC (300.18K), CITADEL ADVISORS LLC (22.16K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (20.07K), J.W. COLE ADVISORS, INC. (12.50K), GEODE CAPITAL MANAGEMENT, LLC (3.04K).
• Leading sellers of HCW Biologics stock in December 2025 included DRW Securities, LLC (48.16K), WELLS FARGO & COMPANY/MN (700), CITIGROUP INC (310).
• The top 10 institutional holders of HCW Biologics for the quarter ending December 2025 included ARMISTICE CAPITAL, LLC (300.18K), DRW Securities, LLC (35.28K), CITADEL ADVISORS LLC (22.16K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (20.07K), VANGUARD GROUP INC (15.43K), GEODE CAPITAL MANAGEMENT, LLC (14.04K), J.W. COLE ADVISORS, INC. (12.50K), Golden State Wealth Management, LLC (10.00K), Tower Research Capital LLC (TRC) (4.50K), UBS Group AG (1.74K).